Saturday 17 October 2026 Export BBIO’s income statement to Excel — free account

BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $502.1 million, up 126.3% from fiscal 2024. In the quarter to June 2026, revenue grew 120.4%, EPS grew 17.9%, free cash flow grew 16.6% and total debt rose 4.22%, each against the same quarter a year earlier.

66.39 0.74 −1.10%

Follow BBIO

Alert me

Market cap: $13.1B
P/E: 0.0×
Fwd P/E: −31.1×
Dividend yield: —
F-score: 3/9
Altman Z: −3.45
Beneish M: 8.17
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 105.05

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	7	3	1	7	3	2	4	4	3	1	1	—

Insider Ownership 10.59%

Capital & Financial Ratios $m

Market Cap 13,120.00

Revenue 713.07

Net Income (702.02)

Free Cash Flow (435.39)

Net Debt 1,207.37

Current Ratio 1.23

Debt/Equity (0.77)

P/E ratio 0.00

Fwd P/E (31.10)

P/S ratio 18.23

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth 26.62%

Next Y EPS Growth 94.90%

Next Y revenue growth 105.94%

Next 5Y EPS Growth 73.02%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 14.02%

10-year low 10-year high

EV/Sales against its own 10 years 0.82%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	452	681	587	720
Receivables	2	5	139	254
Inventory	—	—	27	53
Other	—	—	—	—
	478	721	798	1,093

	2023	2024	2025	Q'26
Payables	11	10	36	27
ST’ Debt	—	—	—	—
Other	—	33	120	192
	144	154	288	891

Compound Annual Growth %

	10y	5y	3y
Sales	—	127.44%	86.30%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	0.00%	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	195	244	—	—	—
’25	117	111	121	154	502
’24	211	2	3	6	222
’23	2	2	4	2	9
’22	2	74	0	2	78
’21	0	54	2	13	70
’20	—	—	8	0	8

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(197)	(71)	—	—	—
’25	(199)	(81)	(110)	(56)	(446)
’24	(220)	75	(181)	(195)	(521)
’23	(144)	(113)	(145)	(125)	(528)
’22	(161)	(30)	(135)	(93)	(419)
’21	(151)	(92)	(122)	(134)	(498)
’20	(84)	(88)	(132)	(96)	(400)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(197)	(72)	—	—	—
’25	(201)	(86)	(112)	(56)	(456)
’24	(221)	72	(182)	(199)	(530)
’23	(144)	(114)	(146)	(125)	(529)
’22	(161)	(34)	(136)	(94)	(426)
’21	(153)	(94)	(163)	(136)	(546)
’20	(88)	(88)	(132)	(99)	(407)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.84)	(0.78)	—	—	—
’25	(0.88)	(0.95)	(0.95)	(1.00)	(3.78)
’24	(0.20)	(0.39)	(0.86)	(1.40)	(2.88)
’23	(0.92)	(0.98)	(1.08)	(0.96)	(3.95)
’22	(1.35)	(0.07)	(0.93)	(0.92)	(3.26)
’21	(1.18)	(0.66)	(1.06)	(1.01)	(3.90)
’20	(0.78)	(1.03)	(0.98)	(1.01)	(3.80)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	17.61	14.23	11.20	4.98	7.10	21.62	27.53	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	48.36	71.56	73.50	18.13	44.32	41.04	78.44
People
People	Employees	—	—	152	248	385	578	392	550	730	839
	Revenue/emp, $m	—	—	0.00	0.16	0.02	0.12	0.20	0.02	0.30	0.60
Income, $m
Income, $m	Revenue	—	—	—	41	8	70	78	9	222	502
	Gross margin, %	—	0.00	—	93.84	100.00	95.53	95.58	73.71	98.25	95.82
	EBT	—	(44)	(169)	(289)	(505)	(586)	(485)	(653)	(542)	(733)
	EBT margin, %	—	0.00	0.00	(711.50)	(6,127.87)	(841.20)	(624.17)	(7,021.94)	(244.34)	(145.89)
	Net income	—	(44)	(169)	(289)	(505)	(586)	(485)	(653)	(543)	(733)
	Depreciation	—	0	—	1	1	6	7	15	14	11
Per share, $
Per share, $	Revenue	—	0.00	0.00	0.39	0.07	0.48	0.53	0.06	1.19	2.62
	Earnings	—	(1.43)	(2.74)	(2.48)	(3.80)	(3.90)	(3.26)	(3.95)	(2.88)	(3.78)
	Cash flow	—	(1.32)	(2.21)	(2.41)	(3.39)	(3.45)	(2.84)	(3.24)	(2.80)	(2.33)
	Capex	—	(0.02)	(0.04)	(0.03)	(0.06)	(0.33)	(0.04)	(0.01)	(0.05)	(0.05)
	Free cash flow	—	(1.34)	(2.25)	(2.44)	(3.45)	(3.78)	(2.89)	(3.25)	(2.85)	(2.38)
	Book value	—	0.00	6.11	4.51	0.90	(6.01)	(8.43)	(8.25)	(7.83)	(10.84)
	Shares, m	—	31	62	105	118	144	147	163	186	192
Valuation, ×
Valuation, ×	P/E	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	—	—	—	0.00	171.91	34.54	13.62	707.83	23.01	29.18
	P/B	—	—	—	7.78	78.97	0.00	0.00	0.00	0.00	0.00
	EV/Sales	—	—	—	0.00	169.25	47.03	29.09	845.29	27.71	31.71
	EV/FCF	—	—	—	(12.64)	(20.29)	(6.41)	(5.30)	(14.82)	(11.61)	(34.94)
Cash, $m
Cash, $m	Operating cash flow	—	(40)	(137)	(254)	(400)	(498)	(419)	(528)	(521)	(446)
	Capex	—	0	(2)	(3)	(8)	(48)	(6)	(1)	(9)	(10)
	Free cash flow	—	(41)	(139)	(256)	(407)	(546)	(426)	(529)	(530)	(456)
Balance, $m
Balance, $m	Working capital	—	88	413	508	547	754	427	334	566	510
	Total debt	—	144	55	100	477	1,704	1,708	1,727	1,721	1,852
	Net debt	—	52	(382)	(446)	(130)	867	1,198	1,275	1,040	1,265
	Shareholders’ equity	—	—	377	474	106	(867)	(1,243)	(1,343)	(1,458)	(2,076)
Returns, %
Returns, %	ROA	—	(10.86)	(56.24)	(47.53)	(67.21)	(65.55)	(58.83)	(110.00)	(73.11)	(78.14)
	ROIC	—	(52.71)	0.00	(604.41)	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	—	(24.07)	(82.69)	(61.24)	(154.74)	147.89	45.60	49.74	38.26	41.03

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
EXEL Exelixis, Inc.	$15.6B	18.8×	16.7×	+10.63% (above 0%: growing)	+25.00% (above 0%: growing)	+557.25% (above 0%: growing)	96.71%	39.51%	Compare
ASND Ascendis Pharma A/S	$14.9B	16.3×	13.0×	+119.88% (above 0%: growing)	n/m	+2,335.93% (above 0%: growing)	91.85%	64.98%	Compare
JAZZ Jazz Pharmaceuticals PLC	$13.9B	13.8×	17.3×	+15.55% (above 0%: growing)	n/m	+140.99% (above 0%: growing)	90.37%	20.54%	Compare
HALO Halozyme Therapeutics, Inc.	$13.8B	34.6×	10.6×	+47.67% (above 0%: growing)	+44.12% (above 0%: growing)	+141.18% (above 0%: growing)	83.54%	59.80%	Compare
BBIO BridgeBio Pharma, Inc.	$13.1B	— (loss-making)	— (loss-making)	+120.39% (above 0%: growing)	n/m	+16.59% (above 0%: growing)	93.83%	(43.94%)
CORT Corcept Therapeutics Incorporated	$12.3B	212×	139×	+31.74% (above 0%: growing)	+21.21% (above 0%: growing)	−29.89% (below 0%: shrinking)	98.41%	16.12%	Compare
SMMT Summit Therapeutics PLC	$12.3B	— (loss-making)	— (loss-making)	−100.00% (below 0%: shrinking)	n/m	−112.80% (below 0%: shrinking)	0.00%	0.00%	Compare
TECH Bio-Techne Corp	$11.4B	62.0×	37.6×	+1.33% (above 0%: growing)	n/m	−6.83% (below 0%: shrinking)	65.82%	23.13%	Compare
BMRN BioMarin Pharmaceutical Inc.	$10.9B	144×	16.1×	+19.91% (above 0%: growing)	−81.60% (below 0%: shrinking)	−20.28% (below 0%: shrinking)	79.51%	11.21%	Compare
Median of peers	$13.0B	34.6×	16.7×	+17.73%	+23.11%	+67.08%	86.96%	21.84%

All 614 Biotechnology stocks →

BridgeBio Pharma, Inc. (BBIO) key facts

Strength: BridgeBio Pharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $502.1 million, up 126.3% from fiscal 2024.
BridgeBio Pharma, Inc. (BBIO) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, BBIO traded at $66.39, a market capitalization of $13.1 billion.
Return on equity was 41.0% and debt-to-equity -0.77.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −3.45 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.